Show simple item record

dc.contributor.authorAltenburg, Arwen F
dc.contributor.authorvan Trierum, Stella E
dc.contributor.authorde Bruin, Erwin
dc.contributor.authorde Meulder, Dennis
dc.contributor.authorvan de Sandt, Carolien E
dc.contributor.authorvan der Klis, Fiona R M
dc.contributor.authorFouchier, Ron A M
dc.contributor.authorKoopmans, Marion P G
dc.contributor.authorRimmelzwaan, Guus F
dc.contributor.authorde Vries, Rory D
dc.date.accessioned2018-05-04T09:22:27Z
dc.date.available2018-05-04T09:22:27Z
dc.date.issued2018-04-24
dc.identifier.citationEffects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. 2018, 8 (1):6474 Sci Repen
dc.identifier.issn2045-2322
dc.identifier.pmid29692427
dc.identifier.doi10.1038/s41598-018-24820-2
dc.identifier.urihttp://hdl.handle.net/10029/621897
dc.description.abstractThe replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record. However, pre-existing vector-specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing immunity. Nonetheless, orthopoxvirus-specific pre-existing immunity reduced the induction of antigen-specific antibodies under specific conditions and completely prevented induction of antigen-specific T cell responses by rMVA-based vaccination. Notably, antibodies induced by vaccinia virus vaccination, both in mice and humans, were not capable of neutralizing MVA. Thus, when using rMVA-based vaccines it is important to consider the main correlate of protection induced by the vaccine, the vaccine dose and the orthopoxvirus immune status of vaccine recipients.
dc.language.isoenen
dc.rightsArchived with thanks to Scientific reportsen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEffects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.en
dc.typeArticleen
dc.identifier.journalSci Rep 2018; 8(1):6474en
refterms.dateFOA2018-12-18T14:25:02Z
html.description.abstractThe replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record. However, pre-existing vector-specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing immunity. Nonetheless, orthopoxvirus-specific pre-existing immunity reduced the induction of antigen-specific antibodies under specific conditions and completely prevented induction of antigen-specific T cell responses by rMVA-based vaccination. Notably, antibodies induced by vaccinia virus vaccination, both in mice and humans, were not capable of neutralizing MVA. Thus, when using rMVA-based vaccines it is important to consider the main correlate of protection induced by the vaccine, the vaccine dose and the orthopoxvirus immune status of vaccine recipients.


Files in this item

Thumbnail
Name:
s41598-018-24820-2.pdf
Size:
1.993Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Archived with thanks to Scientific reports
Except where otherwise noted, this item's license is described as Archived with thanks to Scientific reports